Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live + Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Phase 3Completed 1 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Measles
Conditions
Measles, Mumps, Rubella, Varicella
Trial Timeline
Feb 1, 1999 → Jul 1, 2001
NCT ID
NCT00092391About Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live + Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck)
Comparator: M-M-R(TM) II, measles, mumps, and rubella virus vaccine live + Comparator: VARIVAX(TM) Varicella Virus Vaccine Live (Oka-Merck) is a phase 3 stage product being developed by Merck for Measles. The current trial status is completed. This product is registered under clinical trial identifier NCT00092391. Target conditions include Measles, Mumps, Rubella.
What happened to similar drugs?
4 of 17 similar drugs in Measles were approved
Approved (4) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00092391 | Phase 3 | Completed |
Competing Products
20 competing products in Measles